Please assess the completion status of the following clinical trial:

Trial Title: Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A female who enrolled in the immunological subset of the 580299-013 study, received the three doses of vaccine/control according to the treatment allocation and completed the 580299-013 study.~* Written informed assent obtained from the subject and written informed consent obtained from a parent or legally acceptable representative of the subject.~Exclusion Criteria:~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs occurring less than 3 months prior to blood sampling.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding blood sampling.

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
- Havrix Group (Type: ACTIVE_COMPARATOR): Subjects received 3 doses of Havrix™ (hepatitis A vaccine \[HAV\]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).